Published in J Cancer Res Clin Oncol on April 24, 2011
Molecular biomarkers screened by next-generation RNA sequencing for non-sentinel lymph node status prediction in breast cancer patients with metastatic sentinel lymph nodes. World J Surg Oncol (2015) 0.78
Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. Nat Rev Cancer (2017) 0.78
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA (2011) 16.68
A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol (2003) 5.20
Sentinel lymphadenectomy in breast cancer. J Clin Oncol (1997) 3.89
TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell (2003) 2.87
Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg (1997) 2.49
Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest (2007) 2.28
Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol (2009) 1.90
Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol (1993) 1.88
Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol (2009) 1.67
Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer (2007) 1.63
Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer (2008) 1.50
Models for predicting non-sentinel lymph node positivity in sentinel node positive breast cancer: the importance of scoring system. Int J Clin Pract (2008) 1.50
New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer (2008) 1.45
Can axillary dissection be avoided in patients with sentinel lymph node metastasis? J Surg Oncol (2006) 1.43
A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg (2008) 1.40
R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med (Berl) (2008) 1.33
An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat (2005) 1.27
Validation of breast cancer nomograms for predicting the non-sentinel lymph node metastases after a positive sentinel lymph node biopsy in a multi-center study. Eur J Surg Oncol (2009) 1.24
Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node. J Natl Cancer Inst (2008) 1.07
Tumor lymphangiogenesis and metastatic spread-new players begin to emerge. Int J Cancer (2006) 1.02
Direct role of PDGF-BB in lymphangiogenesis and lymphatic metastasis. Cell Cycle (2005) 0.96
A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol (2008) 0.94
Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion. Clin Cancer Res (2008) 0.93
Completion of axillary dissection for a positive sentinel node: necessary or not? Curr Oncol Rep (2009) 0.89
Multiplexed immunoassays for the analysis of breast cancer biopsies. Anal Bioanal Chem (2010) 0.86
Ljubljana nomograms for predicting the likelihood of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel lymph node. Breast Cancer Res Treat (2010) 0.80
Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up. Ann Surg Oncol (2010) 0.79
Is axillary dissection needed in node-positive breast cancer? Expert Rev Anticancer Ther (2008) 0.77
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet (2010) 5.48
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med (2012) 4.24
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Systemic hypothermia after neonatal encephalopathy: outcomes of neo.nEURO.network RCT. Pediatrics (2010) 3.58
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst (2013) 3.46
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol (2012) 2.72
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
The significance of gastric residuals in the early enteral feeding advancement of extremely low birth weight infants. Pediatrics (2002) 2.30
Work-life balance of German gynecologists: a web-based survey on satisfaction with work and private life. Arch Gynecol Obstet (2013) 2.27
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
The Tokuhashi score: significant predictive value for the life expectancy of patients with breast cancer with spinal metastases. Spine (Phila Pa 1976) (2005) 1.72
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol (2010) 1.71
Does guideline-adherent therapy improve the outcome for early-onset breast cancer patients? Oncology (2010) 1.70
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol (2009) 1.68
Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol (2010) 1.63
Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer (2007) 1.62
Assessment of COPD severity by computed tomography: correlation with lung functional testing. Clin Imaging (2010) 1.59
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Is a controlled randomised trial the non-plus-ultra design? A contribution to discussion on comparative, controlled, non-randomised trials. Contemp Clin Trials (2013) 1.43
Evaluation of a health promotion program in children: Study protocol and design of the cluster-randomized Baden-Württemberg primary school study [DRKS-ID: DRKS00000494]. BMC Public Health (2012) 1.43
Uterine arteriovenous malformations induced after diagnostic curettage: a systematic review. Arch Gynecol Obstet (2011) 1.42
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Ovarian metastasis of a lymphoma presenting as primary ovarian cancer. Onkologie (2009) 1.40
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology (2008) 1.37
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol (2009) 1.31
Periodontal infections and coronary heart disease: role of periodontal bacteria and importance of total pathogen burden in the Coronary Event and Periodontal Disease (CORODONT) study. Arch Intern Med (2006) 1.30
Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. Hum Mutat (2011) 1.29
Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res (2013) 1.27
IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One (2009) 1.25
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases. Cancer Lett (2006) 1.21
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol (2013) 1.20
Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res (2002) 1.18
Exacerbation of a maternal hiatus hernia in early pregnancy presenting with symptoms of hyperemesis gravidarum: case report and review of the literature. Arch Gynecol Obstet (2010) 1.18
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.17
Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy. Nephron Clin Pract (2003) 1.17
Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis (2005) 1.16
Measuring power during the sit-to-stand transfer. Eur J Appl Physiol (2003) 1.15
Effects of guideline adherence in primary breast cancer--a 5-year multi-center cohort study of 3976 patients. Breast (2010) 1.15
Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients. Breast (2011) 1.14
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Prognosis scores of Tokuhashi and Tomita for patients with spinal metastases of renal cancer. Ann Surg Oncol (2006) 1.12
Prospective evaluation of factors influencing success rates of sentinel node biopsy in 814 breast cancer patients. Cancer Biother Radiopharm (2004) 1.10
Chlamydia trachomatis infection as a risk factor for infertility among women in Ghana, West Africa. Am J Trop Med Hyg (2008) 1.10
Risk awareness and transparency. Dtsch Arztebl Int (2013) 1.10
Creating a blended learning module in an online master study programme in oncology. Educ Health (Abingdon) (2015) 1.09
Gender-specific prevalences of fatty liver in obese children and adolescents: roles of body fat distribution, sex steroids, and insulin resistance. J Clin Endocrinol Metab (2009) 1.07
Retziusscopy: a minimal invasive technique for the treatment of retropubic hematomas after TVT procedure. Eur J Obstet Gynecol Reprod Biol (2011) 1.05
Economic evaluation of URMEL-ICE, a school-based overweight prevention programme comprising metabolism, exercise and lifestyle intervention in children. Eur J Health Econ (2011) 1.05
Low-risk variants FGFR2, TNRC9 and LSP1 in German familial breast cancer patients. Int J Cancer (2010) 1.03
Protein microarrays for personalized medicine. Clin Chem (2010) 1.03
Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics (2002) 1.03
[Short version of the guideline "Early Detection of Breast Cancer in Germany"]. Z Arztl Fortbild Qualitatssich (2004) 1.03
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther (2002) 1.03
CT-guided lung biopsy: incidence of pneumothorax after instillation of NaCl into the biopsy track. Eur Radiol (2008) 1.03
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 1.01
Hemorrhagic complications associated with tension-free vaginal tape procedure. Obstet Gynecol (2004) 1.01
VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. Gynecol Oncol (2012) 0.99
Cognitive function in bulbar- and spinal-onset amyotrophic lateral sclerosis. A longitudinal study in 52 patients. J Neurol (2005) 0.99
Coordination of strength exertion during the chair-rise movement in very old people. J Gerontol A Biol Sci Med Sci (2007) 0.99
Role of SIRT1 in homologous recombination. DNA Repair (Amst) (2010) 0.99
Sequential multiplex analyte capturing for phosphoprotein profiling. Mol Cell Proteomics (2010) 0.99
Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol (2003) 0.99
Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res (2004) 0.99
Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. Oncol Rep (2005) 0.98
Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology (2002) 0.98
On the difference of micronucleus frequencies in peripheral blood lymphocytes between breast cancer patients and controls. Mutagenesis (2006) 0.98
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. Oncol Rep (2004) 0.97
Intervention study shows outpatient cardiac rehabilitation to be economically at least as attractive as inpatient rehabilitation. Clin Res Cardiol (2009) 0.97
Global cerebral atrophy in early stages of Huntington's disease: quantitative MRI study. Neuroreport (2004) 0.96
Tspan-1 is a tetraspanin preferentially expressed by mucinous and endometrioid subtypes of human ovarian carcinomas. Cancer Lett (2008) 0.96
Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer (2012) 0.96
Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res (2003) 0.95
Angiogenesis during primate placentation in health and disease. Reproduction (2003) 0.95
A generic operational strategy to qualify translational safety biomarkers. Drug Discov Today (2011) 0.94
Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasiveness with expression of CD24. Tumour Biol (2002) 0.93
First Revision of the German S3 Guideline 'Diagnosis, Therapy, and Follow-Up of Breast Cancer' Breast Care (Basel) (2008) 0.93
Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion. Clin Cancer Res (2008) 0.93